KMT2A and acute lymphoblastic leukemia: Although KMT2A rearrangement has been identified as a high-risk marker in both ALL and AML, it is believed that the specific fusion partner plays an indispensable role in pathogenesis and can influence the outcome to some extent [14, 15].